QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

STE

QT66STERIS plc
NYSE·Healthcare·Medical - Devices·USA
Latest market price
202.61
+3.21+1.61%
OverviewShort InterestFilings
STEQT66STERIS plc·NYSE
OverviewShort InterestFilings
202.61+1.61%
TA
Loading chart...
Screen all →
ABT-0.10%$88.41ISRG+1.14%$406.78SYK+2.21%$307.80MDT+1.54%$79.34BSX+0.76%$45.29EW+0.78%$87.36DXCM+1.74%$72.47RMD+1.26%$188.63
Snapshot
Index-P/E24.98EPS (ttm)7.93
Insider Own0.45%
Shs Outstand97.46M
Perf Week-2.22%
Market Cap19.43BForward P/E16.62EPS next Y12.19Insider Trans0.00%Shs Float-Perf Month-5.51%
Enterprise Value21.08BPEG0.90EPS next Q2.52Inst Own-Short Float-Perf Quarter-7.03%
Income777.32MP/S3.27EPS this Y40.76%Inst Trans-Short Ratio-Perf Half Y-19.93%
Sales5.94BP/B2.72EPS next Y9.19%ROA7.29%Short Interest-Perf YTD-20.08%
Book/sh73.85P/C14.57EPS next 5Y8.74%ROE11.05%52W High269.43 -24.80%Perf Year-14.54%
Cash/sh4.51P/FCF19.98EPS past 3/5Y-ROIC8.47%52W Low195.14 3.83%Perf 3Y-
Dividend Est.2.52 (1.24%)EV/EBITDA11.53Sales past 3/5Y9.38% 13.82%Gross Margin44.25%Volatility1.68% 1.72%Perf 5Y-
Dividend TTM2.52 (1.24%)EV/Sales3.55EPS Y/Y TTM67.42%Oper. Margin18.56%ATR (14)5.32Perf 10Y-
Dividend Ex-DateJun 08, 2026Quick Ratio1.54Sales Y/Y TTM8.70%Profit Margin13.18%RSI (14)38.02Recom2.00
Dividend Gr. 3/5Y10.06% 9.28%Current Ratio2.09EPS Q/Q21.98%SMA20-3.73%Beta0.60Target Price269.50
Payout30.90%Debt/Eq0.29Sales Q/Q7.22%SMA50-5.58%Rel Volume1.97Prev Close199.40
Employees18,000LT Debt/Eq0.27EarningsAug 05SMA200-15.18%Avg Volume799.99KPrice202.61
IPO DateJun 01, 1992Option/ShortYes / YesEPS/Sales Surpr.-0.70% -0.44%Net Debt/EBITDA0.90Volume1,575,294Change1.61%
Analyst Ratings
DateActionAnalystRatingTarget
May-21-26ReiteratedPiper SandlerOverweight$260 → $270
May-13-26ReiteratedKeybancOverweight$265 → $269
Jul-15-25UpgradeMorgan StanleyEqual Weight → Overweight
Oct-24-24UpgradePiper SandlerNeutral → Overweight$225 → $260
Sep-03-24ReiteratedKeyBancOverweight$255 → $265
May-10-24ReiteratedPiper SandlerNeutral$225
Apr-04-24ReiteratedWolfe Research$245
Apr-14-23DowngradePiper SandlerOverweight → Neutral
Sep-23-22DowngradeNeedhamBuy → Hold
May-26-21UpgradeNeedhamHold → Buy
Latest News
Jun-18-26
Jun-18-2608:20PM
Dividend Champion, Contender, And Challenger Highlights: Week Of June 21SeekingAlpha
Jun-15-26
Jun-15-2602:02PM
Is STERIS Stock Underperforming the Dow?Yahoo
Jun-12-26
Jun-12-2605:11AM
Steris (STE) Stock After Q4 Miss And 2027 Outlook What The Valuation Signals NowYahoo
Jun-10-26
Jun-10-2607:30PM
[Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 19.6 Billion by 2035 at a 5.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)Yahoo
03:30PM
Why Is Steris (STE) Up 1% Since Last Earnings Report?Yahoo
03:30PM
Why Is Steris (STE) Up 1% Since Last Earnings Report?Yahoo
Jun-09-26
Jun-09-2605:34PM
Are Options Traders Betting on a Big Move in STERIS Stock?Yahoo
04:56PM
Steris: Stable, Steady And AppealingSeekingAlpha
Jun-08-26
Jun-08-2610:29AM
3 Cash-Producing Stocks We Think Twice AboutYahoo
10:29AM
3 Cash-Producing Stocks We Think Twice AboutYahoo
10:29AM
3 Cash-Producing Stocks We Think Twice AboutYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue5,9355,9365,460
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A3,3093,3093,057
Gross Profit2,6272,6272,403
Selling, General and Administrative Excl. Other1,4081,4081,334
Research and Development113113108
Other Operating Expense4494
Operating Income1,1021,102867
Interest Expense616186
Unusual Expense
———
Non-Operating Income (Expense)-2-6-16
Net Income Before Taxes1,0481,047796
Income Taxes263262185
Consolidated Net Income782785615
Net Income From Continuing Operations785785612
Net Income782785615
EPS (Recurring)7.957.936.24
EPS (Basic, Before Extraordinaries)7.957.936.24
EPS (Diluted)7.937.936.20
EBITDA1,8281,5951,359
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio25.5527.89—
Price To Sales Ratio3.353.65—
Gross Margin44.2644.2644.01
Operating Margin18.5718.5615.88
Net Margin13.1813.2211.26
Shares Outstanding989899
Market Capitalization19,85621,671—
Operating Lease Expense
———
Insider Trading Volume
$210.65$193.23$175.82$158.41$140.99● Close Price0.00M1.46M2.92M4.38M5.83MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zangerle John AdamSr. VP, Gen Counsel, and Sec.Jun 15 '26Sale209.281,419296,96835,259Jun 16 12:00 AM
Carestio Daniel APresident and CEOJun 05 '26Sale212.001,374291,28863,647Jun 08 12:00 AM
Carestio Daniel APresident and CEOJun 04 '26Sale214.643,054655,51165,021Jun 08 12:00 AM
Burton Karen LSr. Vice Pres., CFOJun 02 '26Option Exercise209.766613,84413,464Jun 04 12:00 AM
Breeden Richard CDirectorJun 02 '26Option Exercise71.407,562539,92640,445Jun 04 12:00 AM
Breeden Richard CDirectorJun 02 '26Sale209.511,481310,28438,964Jun 04 12:00 AM
FELDMANN CYNTHIA LDirectorMar 05 '26Option Exercise152.326,196943,7743,803Mar 06 12:00 AM
FELDMANN CYNTHIA LDirectorMar 05 '26Sale237.213,098734,877705Mar 06 12:00 AM
Madsen JuliaSr. VP and GM, Life SciencesNov 21 '25Sale262.002,136559,63210,710Nov 25 12:00 AM
Madsen JuliaSr. VP and GM, Life SciencesNov 21 '25Option Exercise128.2210,0161,284,27813,582Nov 25 12:00 AM
Tamaro RenatoV.P. & Corporate TreasurerNov 18 '25Option Exercise182.227,0721,288,66010,731Nov 20 12:00 AM
Tamaro RenatoV.P. & Corporate TreasurerNov 18 '25Sale257.555,0361,297,0395,695Nov 20 12:00 AM
Zangerle John AdamSr. VP, Gen Counsel, and Sec.Nov 11 '25Option Exercise69.7230,0002,091,60048,669Nov 13 12:00 AM
Zangerle John AdamSr. VP, Gen Counsel, and Sec.Nov 11 '25Sale265.1415,0003,977,10033,669Nov 13 12:00 AM
Carestio Daniel APresident and CEOOct 06 '25Sale241.8215938,44951,096Oct 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR